for the treatment of dry eye1

An innovative formulation of cyclosporine A delivered with advanced proprietary nanomicellar technology for increased ocular penetration2,3

Sign up for updates

Get alerted when CEQUA
becomes available.

Sign up now  Right ArrowAn icon represets a right arrow.">

In the news

Read the press
release for CEQUA.

View now  Right ArrowAn icon represets a right arrow.">

Journal article

Read the published journal article for the Phase 2/3 trial that evaluated the safety and efficacy of CEQUA.

View now  Right ArrowAn icon represets a right arrow.">

CEQUA™ (cyclosporine ophthalmic solution) 0.09% is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).



Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.

Use with Contact Lenses: CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.


The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.

Please see the Full Prescribing Information.

References: 1. CEQUA™ [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; 2018. 2. Mitra AK, Weiss SL, inventors; Sun Pharma Global FZE, assignee. Topical formulations and uses thereof. US patent 9,937,225 B2. April 10, 2018. 3. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.